

Republic of the Philippines

Department of Education

REGION VIII - EASTERN VISAYAS

September 26, 2024

REGIONAL MEMORANDUM

No. 1163

s. 2024

INTERIM GUIDELINES ON THE RESUMPTION OF SCHOOL-BASED IMMUNIZATION (SBI) PROGRAM AFTER THE COVID-19 PANDEMIC

To:

Schools Division Superintendents

Head, Health and Nutrition Section

Public Elementary and Secondary School Heads

All Others Concerned

- 1. With the full resumption of face-to-face classes, learners have a high risk of contracting vaccine-preventable diseases (VPD) such as measles, rubella, tetanus, diphtheria, and human papillomavirus (HPV); thus, shift back from community-based to school-based setting is imperative.
- 2. All Schools Division Offices (SDOs) and schools shall provide full support in the conduct of the activity. School health personnel are expected to closely coordinate with the provincial/city health officers in the conduct of vaccination activities.
- 3. Attached is a copy of the Interim Guidelines on the Resumption of SBI Program after the COVID-19 Pandemic.

4. Immediate dissemination and compliance with this Memorandum are desired.

EVELYN R. FETALVERO CESO III

Regional Director

Enclosures: As stated

References: DM-OUOPS-2024-03-06789

To be indicated in the Perpetual Index under the following subjects:

OPLAN KALUSUGAN SA DEPED

SCHOOL-BASED IMMUNIZATION

ESSD-SHNU-ALSL









Telephone No.: (053) 832-5738 Email Address: region8@deped.gov.ph

Website: region8.deped.gov.ph





Republika ng Pilipinas

Department of Education

OFFICE OF THE UNDERSECRETARY FOR OPERATIONS

MEMORANDUM DM-OUOPS-2024-63-64789

TO

: REGIONAL DIRECTORS

SCHOOLS DIVISION SUPERINTENDENTS

PUBLIC AND PRIVATE ELEMENTARY AND SECONDARY SCHOOLS

ALL OTHERS CONCERNED

FROM

: ATTY. REVSEE A. ESCOBEDO

Undersecretary for Operations

SUBJECT

: INTERIM GUIDELINES ON THE RESUMPTION OF SCHOOL-BASED

IMMUNIZATION (SBI) PROGRAM AFTER THE COVID-19 PANDEMIC

DATE : August 19, 2024

- 1. Immunization provide protection against vaccine-preventable diseases (VPDs) such as measles, rubella, tetanus, diphtheria and human papillomavirus (HPV). In 2013, the School Based Immunization (SBI) Program was institutionalized and conducted every August nationwide in all public schools until the COVID-19 pandemic. IN 2020, SBI shifted from school-based to community-based setting due to mobility restrictions and suspension of in-person classes in schools during the peak of the COVID-19 pandemic.
- 2. The full resumption of face-to-face classes exposes school learners to high risk of contracting VPDs, thus it is imperative that the SBI Program shall be implemented and shifted back to school-based from community-based setting the full resumption of face-to-face classes, school learners are at high risk of contracting VPDs.
- The Interim Guidelines on the Resumption of School-Based Immunization after the COVID-19 Pandemic are contained in the Enclosure.
- 4. Parental consent must be secured prior to the conduct of the activity.
- Regional Directors, Schools Division Superintendents and other school officials are
 enjoined to provide full support to in the conduct of the activity. School health personnel
 are expected to closely coordinate with the regional/provincial/city health officers in the
 conduct of the vaccination activities.
- For more information, all concerned may contact Dr. Maria Corazon C. Dumlao, Chief, Health Program Officer, Bureau of Learner Support Services-School Health Division at (02)8632-9935 and email at blss.shd@deped.gov.ph.
- 7. Immediate dissemination of this Memorandum is desired.

Incls.: As stated.









Republic of the Philippines DEPARTMENT OF HEALTH

Office of the Secretary



June 21, 2024

DEPARTMENT MEMORANDUM

No. 2024 - <u>0250</u>

FOR:

ALL UNDERSECRETARIES, ASSISTANT SECRETARIES, DIRECTORS OF BUREAUS, SERVICES, AND CENTERS FOR HEALTH DEVELOPMENT (CHD), MINISTER OF HEALTH - BANGSAMORO AUTONOMOUS REGION IN

MUSLIM MINDANAO (MOH-BARMM), ATTACH AGENCIES, AND OTHERS CONCERNED

SUBJECT:

Interim Guidelines on the Resumption of School-Based

Immunization (SBI) after the COVID-19 Pandemic

I. BACKGROUND

The School-based Immunization (SBI) is a program of the Department of Health (DOH), in coordination with the Department of Education (DepEd), that aims to provide protection against vaccine-preventable diseases (VPDs) such as measles, rubella, tetanus, diphtheria and human papillomavirus (HPV). Since 2013, SBI has been conducted every August nationwide in public schools until the COVID-19 pandemic. The SBI shifted from school-based to community-based setting due to mobility restrictions and suspension of in-person classes in schools during the peak of the COVID-19 pandemic.

With the full resumption of face-to-face classes, school learners are at high risk of contracting VPDs. Thus, the continuity of delivering immunization services, including school-based vaccination, proves to be critical in mitigating public health crises, such as the recent outbreaks of measles and pertussis in certain areas of the country.

In this regard, this issuance aims to provide technical directions for the re-implementation of School-based Immunization services at the school setting.

II. GENERAL GUIDELINES

- A. All SBI services, including Measles-Rubella (MR), Tetanus-diphtheria (Td), and Human Papillomavirus (HPV) vaccination, shall resume its implementation in schools. It is recommended to be rolled out in public schools two (2) months from the start of classes or as agreed upon by DOH and DepEd.
- B. Grade 1 and Grade 7 school children shall be vaccinated with MR and Td vaccines while Grade 4 female school children shall be vaccinated with HPV vaccine. These vaccinations shall follow the appropriate dosages, scheduling and intervals.

- C. A template for informed consent (Annex A), including information, education, and communication (IEC) materials shall be disseminated to parents or guardians prior to the SBI roll—out.
- D. Proper microplanning, coordination, and demand generation activities shall be undertaken by all local government units (LGUs) and local health workers concerned, in collaboration with other stakeholders such as the Department of Education (DepEd) and other national government agencies (NGAs), to ensure the efficiency in managing health resources and highlight the distinction of the MR-Td and HPV school-based immunization from other ongoing vaccination services.

III. SPECIFIC GUIDELINES

A. Preparatory Activities

1. Coordination and Engagement with School Administration

- a. Local health centers shall coordinate with school principals, teachers and school nurses on the conduct of SBI activities and SBI guidelines orientation.
- b. Teachers-in-charge/school nurses shall issue notification letters and consent forms (Annex A) and IEC materials of health services such as immunization to school children upon enrollment. The template for notification letter and informed consent may be accessed through: https://bit.ly/SBIConsentForm.
- c. Schools within the LGU catchment area shall endorse the list of Grade 1, Grade 7, and female Grade 4 children enrolled for the current school year to the local health center.
- d. Local health center staff shall record the endorsed list of eligible school children in the *Recording Forms 1, 2, and 3 (Annexes B, C, D)*. The recording forms may be accessed via: https://tinyurl.com/SBIReporting.

2. Microplanning

- a. All LGUs, assisted by the DOH Development Management Officers (DMO) with coordination and guidance of NIP Managers, shall develop a detailed microplan of the SBI activities. Micro-plans shall include the following:
 - Calculation and identification of the number of children to be vaccinated per immunization session and the vaccination teams needed to prepare immunization schedules for the vaccination team including the schools to be visited;
 - ii. Calculation of the vaccine and other logistics needed including the cold chain equipment:
 - iii. Immunization session plans;
 - iv. Plan for high-risk and hard-to-reach population;
 - v. Crafting of supervisory and monitoring schedule;
 - vi. Follow-up schedule and mop-up plan;
 - vii. Human resource mapping and contingency plan;
 - viii. Demand generation plan;
 - ix. Disease surveillance and reporting;

- x. Adverse Events Following Immunization (AEFI) management plan; and
- xi. Waste management plan
- b. All SBI operational resource requirements shall be consolidated at the city/municipality, provincial and regional levels and included in the costed SBI microplans to be submitted to the higher administrative level.
- c. A standard microplan template which can be accessed through https://tinyurl.com/SBIMicroplanTemplate shall be used by all LGUs.

3. Demand Generation

- a. Engagement of parents and caregivers through Parents and Teacher Association (PTA) meetings and similar activities shall be conducted by schools to ensure uptake among students.
- b. Discussions on vaccination among students shall also be conducted through platforms such as flag ceremonies, as part of lectures for relevant classes, and/or through dedicated teach-in sessions to raise awareness and willingness among students.
- c. Conducting social listening and feedbacking among students and parents shall be done through different channels such as meetings and discussions to identify mis/disinformation that need to be addressed.
- d. LGUs and schools shall mobilize stakeholders to support demand generation activities. This can include the provision of giveaways for successfully vaccinated students, as well as incentives for health workers.
- e. Other interactive community engagement activities such as contests and kick-off/launching activities are also encouraged.

4. Setting up of Vaccination Posts

Local health centers shall coordinate with the school administrators for the use of school facilities as temporary vaccination posts. Temporary vaccination posts shall be well-ventilated and spacious to allow compliance with minimum public health standards. Client flow in the vicinity shall be discussed with school administrators, teachers-in-charge, and school nurses.

5. Establishment of Vaccination Teams

- a. A vaccination team shall be composed of at least three (3) trained personnel composed of one (1) vaccinator, one (1) recorder and one (1) health counselor.
- b. Vaccination teams shall be organized based on the target number of schoolchildren to be vaccinated per immunization session and shall apply the following strategies:
 - i. The LGUs shall identify available human resources for deployment based on the calculated number of vaccination teams needed and identify the gap for possible HR augmentation from stakeholders/ partners in order to reach the target.
 - ii. Schedule vaccination sessions and deployment of vaccination teams giving priority to schools with a high number of eligible children that are close in their respective area of jurisdiction, and/ or areas with cases of measles-rubella. The number of target eligible

populations shall be automatically populated in the SBI Recording Forms.

c. Provided that remaining funds are still available, hiring additional vaccinators and encoders for this activity may be charged under the Locally Funded Project (LFP) funds. Appropriate remuneration through performance-based incentives, and daily subsistence allowance (DSA), transportation allowance, and other immunization-related activities shall be provided to the vaccination teams and may be chargeable against Public Health Management (PHM) funds under DO 2024-0032-B entitled "Further Amendment to the Department Order No. 2024-0032-A dated March 13, 2024, and February 7, 2024, entitled, Guidelines on the Sub-Allotment and Utilization of Funds to Centers for Health Development and Ministry of Health-Bangsamoro Autonomous Region in Muslim Mindanao for the Conduct of CY 2024 Bivalent Oral Polio Vaccine Catch-Up and Supplementation Immunization Activities (bOPV SIA)."

6. Orientation and Training

Pre-deployment orientation and capacity-building activities on SBI guidelines shall be conducted to all primary healthcare workers, vaccination teams, school personnel, and other stakeholders participating in this activity. Orientation shall be provided by the Provincial and City Health Offices with the assistance of the National Immunization Program staff of the CHD.

B. School-Based Immunization (SBI) Roll-Out

1. Conduct of Immunization Sessions

- a. Vaccination teams may request support from Barangay Local Government Units (BLGUs) for the mobilization and transportation of vaccination teams to the different school vaccination locations as scheduled.
- b. Only students from the school itself can take part in the immunization sessions held on school premises.
- c. Consenting parents/guardians of Grade 1, Grade 7, and female Grade 4 school children shall complete and submit the consent forms on/or before the scheduled SBI immunization session.
- d. School children shall bring their Routine Immunization Cards or Mother and Child booklets on the day of immunization for confirmation of their vaccination history.
- e. The vaccinator shall conduct a quick health assessment prior to administration of MR, Td, and HPV vaccines using the recommended form (Annex G) to ensure that the child is well enough to be vaccinated.
- f. Antigens administered during the SBI shall be reflected as a supplemental dose in the Routine Immunization Card, Mother and Child booklet, or SBI vaccination card.
- g. If the Routine Immunization Card or Mother and Child Booklet is not available, an SBI vaccination card shall be provided by the local health center (Annex H).
- h. Parents and guardians must be reminded to keep the child's immunization card as it will be used as a means for verification of the child's vaccination status.

2. MR-Td and HPV Immunization Target Population, Schedules, and Operations

- a. Local health center staff shall be in charge of checking the school children's vaccination status and consolidating informed consents for SBI.
- b. Target school children shall receive the following recommended vaccines:

Table 1. Recommended vaccines for school-based immunization

Vaccine	Vaccination History	Vaccine Schedule	Dosage
Grade 1 Studen			
MR	Irrespective	One (1) dose	0.5mL SQ, Right upper arm (posterior triceps) each dose
Td	Irrespective	One (1) dose	0.5mL, IM, Left deltoid
Grade 7 Studen	ts		
MR	Irrespective	One (1) dose	0.5mL SQ, Right upper arm (posterior triceps)
Td	Irrespective	One (1) dose	0.5mL, IM, Left deltoid
Grade 4 Female	Students in selected i	HPV implementing a	reas only (Annex I)
		HPV1	0.5ml IM, left deltoid
HPV	Zero (0) dose	HPV 2, at least 6 months from 1st dose	0.5ml, IM left deltoid
	One (1) or 2 doses from previous year implementation	Vaccination not required	None

- c. Timing and spacing of MR, Td, or HPV vaccines with other vaccines shall follow standard immunization rules:
 - i. Inactivated vaccines such as Td and HPV can be given at any interval even if another vaccine was previously injected to the child (ie. rabies toxoid or MR vaccine).
 - ii. Live, attenuated vaccines such as MR can be administered on the following conditions:
 - 1. If not given simultaneously/on the same day after another live attenuated vaccine (e.g., varicella), administer following a 28-day interval
 - 2. If not given simultaneously/on the same day after an inactivated vaccine (ie. Td and HPV), administer any time

- iii. Co-administration of vaccines in one session must be done using separate syringes and different injection sites.
- d. All vaccinated students shall be recorded in Recording Forms 1, 2 and 3.
- e. In compliance with Healthy Learning Institutions standards, private schools who wish to participate in school-based immunization shall directly coordinate with their respective local health centers. Eligible private school children shall also be recorded in the *Recording Forms*.
- f. End-of-cycle mop-up activities. To achieve maximum immunization coverage, mop-up activities shall be provided to those students who have not completed their recommended immunization schedule. The local health center shall inform the teacher-in-charge or school nurse of available activities. This catch-up may include the scheduling of an additional vaccine day, the option for some students to receive catch-up vaccines with their peers in other classes or accessing the immunization session from the local health center.
 - i. A mop-up activity may be scheduled for all eligible students who were initially deferred for MR, Td, or HPV immunization. Parents or caregivers of eligible students who missed the initial roll-out and catch-up activity and express willingness to get vaccinated shall be referred to the nearest implementing local health center. The student shall be accompanied by their parents and/or caregivers and shall be instructed to bring their duly accomplished consent form, provided that there are still available vaccines.
 - ii. These students shall also be recorded in the Recording Forms.

3. Supply Chain and Logistics Management

a. Vaccine Supply and Inventory Management

- i. All MR, Td, and HPV vaccines and ancillaries shall be provided by the DOH Central Office (CO).
- ii. The quantity of the vaccines and supplies to be allocated and provided to the CHDs shall be based on the consolidated number of enrolled students per region. Requested quantities will be reviewed and adjusted based on inventory reports and vaccine requirements at sub-national levels. Quantification for vaccines and ancillaries shall be done using the microplan template (https://tinyurl.com/SBIMicroplanTemplate).
- iii. All provinces/cities are required to update inventories of MR, Td and HPV vaccines received and issued through the electronic logistics management information system (eLMIS). Such shall be reported weekly.

b. Vaccine Handling and Storage

- i. MR, Td, and HPV vaccines shall be maintained at +2°C to +8°C at all times during distribution, storage, and immunization sessions.
 - 1. MR vaccines lose their potency by 50% when exposed to over 8°C within one (1) hour
 - 2. Td vaccines must never be frozen
 - 3. HPV vaccines should be protected from light
- ii. Vaccine vials with vaccine vial monitors (VVMs) at discard point shall properly be disposed of.

- iii. Vaccine vials and diluents must be placed in standard vaccine carriers.

 Standard vaccine carriers should have four (4) conditioned ice packs.

 Newer vaccine carriers have seven (7) conditioned ice packs.
- iv. Pre-filling of syringes of vaccines is NOT allowed.
- v. Any remaining reconstituted MR vaccine doses must be discarded after six (6) hours or at the end of the immunization session, whichever comes first. Unused reconstituted vaccine MUST NEVER be returned to the refrigerator.
- vi. Open vials of Td vaccine follow the multi-dose vial policy (MDVP). As such, these may be used in subsequent sessions (up to 28 days from opening) provided the following conditions are met:
 - 1. Expiry date has not passed
 - 2. Vaccines are stored under appropriate cold chain conditions
 - 3. Vaccine vial septum has not been submerged in water
 - 4. Aseptic technique has been used to withdraw all doses
 - 5. Vaccine Vial Monitor (VVM) is intact and has not reached the discard point
 - 6. Date is indicated when the vial was opened.
- vii. Excess, unopened vaccine vials brought during immunization sessions shall be marked with a check (✓) before returning to the refrigerator for storage. The check mark shall indicate that the vaccine vial was out of the refrigerator and shall be prioritized for use in the next immunization sessions.

C. Immunization Safety and Adverse Events Following Immunization (AEFI)

- 1. Special precautions must be instituted to ensure that blood-borne diseases will not be transmitted during MR, Td, and HPV immunization. This shall include:
 - a. Use of the auto-disabled syringe (ADS) in all immunization sessions
 - b. Proper disposal of used syringes and needles into the safety collector box and the safety collector boxes with used immunization wastes through the recommended appropriate final disposal for hazardous wastes
 - c. Refraining from pre-filling of syringes, re-capping of needles, and use of aspirating needles, as prohibited
- 2. Fear of injections resulting in fainting has been commonly observed in adolescents during vaccination. Fainting is an immunization anxiety-related reaction. To reduce its occurrence, it is recommended for vaccination sites to be situated in areas not readily visible to the students. Further, the vaccinees shall be:
 - a. Advised to eat before vaccination and be provided with comfortable room temperature during the waiting period
 - b. Seated or lying down while being vaccinated
 - c. Carefully observed for approximately 15 minutes after administration of the vaccine and provided with comfortable room temperature during the observation period
- The decision to administer or delay vaccination because of a current or recent febrile illness depends largely on the severity of the symptoms and their etiology. Mild upper respiratory infections are not generally contraindications to vaccination.

- 4. Adverse events following MR-Td and HPV vaccination are generally non-serious and of short duration. However:
 - a. MR vaccine should NOT be given to a child or adolescent who:
 - i. Has a history of a severe allergic reaction (e.g., anaphylaxis) after a previous dose of the vaccine or vaccine component (e.g. neomycin)
 - ii. Has a known severe immunodeficiency (e.g., from hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, or long-term immunosuppressive therapy or patients with human immunodeficiency virus (HIV) infection who are severely immunocompromised)
 - iii. Pregnant females
 - b. Td vaccine should NOT be given to anyone who had a severe allergic reaction (eg, anaphylaxis) after a previous dose.
 - c. HPV vaccine should NOT be given to adolescents who:
 - i. Had a severe allergic reaction after a previous vaccine dose, or to a component of the vaccine.
 - ii. Has a history of immediate hypersensitivity to yeast.
 - iii. Pregnant females. Although the vaccine has not been causally associated with adverse pregnancy outcomes or adverse events to the developing fetus, data on vaccination in pregnancy are limited.
- 5. Vaccine adverse reactions from any of the vaccines can be found in Annex J of this document. Reporting of AEFI shall follow the existing DOH Guidelines in Surveillance and Response to Adverse Events Following Immunization using the form in Department Circular No. 2023-0206 entitled Advisory on the Implementation and Use of the Revised AEFI Case Investigation Form (CIF) Version 2023.
- 6. All vaccination teams and sites shall have at least one (1) complete AEFI kit with first-line treatment drugs such as epinephrine for allergic reactions and other items for managing the clinical presentation of AEFIs. These kits shall be replenished prior to each vaccination run. All vaccination team members shall be trained to detect, monitor, and provide first aid for AEFI (eg. anaphylaxis) and other health emergencies following immunization. Prompt referral to the nearest health facility must be made in such events.

Table 2. Recommended dosage for epinephrine.

Route of Administration	Frequency of Administration	Dose
Epinephrine 1:1000, IM to the midpoint of the anterolateral aspect of the 3rd of the thigh immediately	Repeat in every 5-15 min as needed until there is a resolution of the anaphylaxis Note: Persisting or worsening cough associated with pulmonary edema is an important sign of epinephrine overdose and toxicity	According to age: • 0.05 mL for less than 1 y.o. • 0.15 mL for 2-6 y.o. • 0.3 mL for 6-12 y.o. • 0.5 mL for older than 12 y.o.

7. The DOH-retained and other government hospitals shall not charge the patient treated for serious AEFI with any fee. In areas where there are no existing or accessible government hospitals/health facilities, serious AEFI cases shall be managed in private institutions and assistance shall be provided by the LGU with support from the DOH in accordance with Administrative Order 2023-0007 entitled Revised Omnibus Guidelines on the Surveillance and Management of Adverse Events Following Immunization (AEFI).

D. Data Management and Monitoring

1. Recording and Reporting

- a. The vaccination teams shall utilize the SBI Recording Forms as masterlists of Grade 1, Grade 7, and female Grade 4 school children.
- b. The total number of children vaccinated per immunization session shall be recorded using the Summary Reporting Form (Annex E) and shall be uploaded in the vaccination dashboard developed by KMITS. Submitted reports shall be analyzed by the DPCB National Immunization Program and submitted to the Public Health Services Cluster (PHSC) as regular updates. The summary reporting form may be accessed via the link: https://tinyurl.com/SBIReporting.
- c. The procedure for submission of reports should adhere to the guidelines provided in Annex F.

2. Monitoring

The Disease Prevention and Control Bureau (DPCB) together with the HPB, EB, KMITS, SCMS and other DOH Bureaus and Offices shall convene weekly meetings with the CHDs and MOH-BARMM every Wednesdays at 10:00 AM until the end of the SBI roll-out period to provide regular updates, review plans and recalibrate strategies, as needed.

IV. ROLES AND RESPONSIBILITIES

A. The Disease Prevention and Control Bureau (DPCB) shall:

- 1. Provide technical assistance and capacity building on the conduct of school-based MR-Td-HPV vaccination, in collaboration with professional and civil societies;
- Coordinate with the Supply Chain Management Service (SCMS) to ensure the availability of vaccines down to the Local Government Unit (LGU) level throughout the implementation of the conduct of school-based MR-Td-HPV vaccination;
- 3. Coordinate with the Health Promotion Bureau with regard to increasing the awareness on the conduct of school-based MR-Td-HPV vaccination; and
- 4. Monitor and evaluate the implementation of school-based MR-Td-HPV vaccination services and outcome indicators.

B. The Health Promotion Bureau (HPB) shall:

- 1. Develop social and behavior change (SBC) strategies for vaccine-preventable diseases and school based immunization (SBI);
- Cascade SBC plan and Communication Packages to the Centers for Health Development (CHDs) and Ministry of Health - Bangsamoro Autonomous Region in Muslim Mindanao (BARMM), partners, and stakeholders for localization and dissemination;
- 3. Collect data on behavioral determinants of target parents and guardians for school-based immunization;
- 4. Support the DepEd in monitoring the accomplishment of indicators and standards related to vaccination in the implementation of the Oplan Kalusugan sa DepEd-Healthy Learning Institutions (OKD-HLI) program, and propose recommendations as appropriate; and
- Evaluate effectiveness of SBC strategies in promoting the conduct of school-based immunization services to guide evidence-based research and policy making.

C. The Epidemiology Bureau (EB) shall enforce the implementation of the existing DOH Guidelines:

- 1. Administrative Order No. 2016-2006 entitled "Adverse Events Following Immunization (AEFI) surveillance and response;" and
- 2. Administrative Order No. 2016-0025 entitled, guidelines on the Referral System for Adverse Events.
- D. The Supply Chain Management Service (SCMS) shall be responsible for the distribution and monitoring of vaccines.
- E. The Communication Office (COM) shall conduct media-facing activities to increase awareness and participation for SBI.
- F. The Centers for Health Development (CHDs) and Ministry of Health-Bangsamoro Autonomous Region in Muslim Mindanao (MOH-BARMM) shall perform the following:

1. The National Immunization Program (NIP) shall:

- a. Conduct orientation for concerned stakeholders regarding the policy and promote its adoption and implementation;
- b. Provide technical assistance and capacity building to LGUs and other partners on the conduct of MR-Td and HPV school-based immunization:
- c. Conduct planning with the Provincial and HUCs, DepEd, and DILG counterparts in the implementation of the SBI;
- d. Submit and analyze submitted weekly accomplishment reports by the Local Government Units through the reporting tool indicated in Section D.1.b;
- e. Evaluate and monitor the implementation of the policy by both public and private sectors in their respective regions; and
- f. Support the LGUs in the reproduction of recording and reporting forms, notification letter and consent forms, quick health assessment forms, immunization cards, among others. as needed.

2. The Health Education and Promotion Units (HEPUs) shall:

- a. Conduct demand generation planning with the LGUs, DepEd, and DILG counterparts in the implementation of the SBI;
- b. Implement social and behavior change (SBC) strategies for vaccine-preventable diseases and school based immunization (SBI):
 - i. Advocate for school administrators and teachers to become champions of school-based immunization:
 - ii. Assist schools in educating, getting the consent of, and mobilizing parents to participate in school-based immunization;
 - iii. Develop and reproduce communication packages and materials to drive demand and support participation in school-based immunization;
 - iv. Harmonize other stakeholders such as the private sector, non-government or civil society organizations, development partners and religious sector to solicit support for immunization program:
- c. Ensure intensification of health promotions regarding SBI together with routine immunization services within their area of influence; and
- d. Support LGUs in the reproduction of materials, as needed.
- 3. The Regional Epidemiology Surveillance Units (RESUs) shall monitor reports of AEFI and conduct vaccine safety surveillance and conduct investigations to reported cases of serious AEFI.
- 4. The Cold Chain Managers and/or the Supply Chain Units shall ensure proper cold chain management at all levels and facilitate allocation and distribution of vaccines to LGUs and monitor stock inventory for immediate replenishment, as needed.
- 5. The Communication Management Units (CMUs) shall develop crisis communication plans for AEFI and issue press releases and engage media to cover the SBI activities.

G. The Department of Education (DepEd) shall:

- 1. Disseminate the policy to all School Division Offices (SDOs) for coordination and planning with their respective counterpart LGUs;
- 2. Disseminate consent forms upon enrollment or at least two (2) weeks prior to actual implementation:
- 3. Conduct health education and promotion activities to parents and students to advocate for immunization in collaboration with the local health center,;
- 4. Provide the needed Master List of Learners (Grade 1, Grade 7, and Female Grade 4) for the year of implementation to their respective counterpart LGUs at least one (1) month prior to the actual SBI rollout; and
- 5. Inform DepEd personnel in SDOs that they may participate voluntarily in the conduct of fixed-site approach school-based immunization. In this regard, the school nurses may:
 - a. Screen immunization records of students for a missed dose, series of doses, or all vaccines due to the learners;
 - b. Administer vaccines to eligible students within the school premises;
 - c. Provide follow-up care and additional vaccinations if required; and

d. Perform the recording, data collection and validation of the number of immunized target populations during the implementation period.

#. Y. The Local Government Units (LGUs) shall:

- 1. Conduct school-based MR-Td and HPV vaccination within their area of influence in accordance to the guidelines set by DOH;
 - 2. Provide localized support or counterpart (i.e. resources, collaterals, others) for the implementation of the policy;
 - 3. Allot funds for reproduction of SBI IEC materials and all other relevant forms for the activity;
 - 4. Develop strategies for conduct of school-based MR-Td-HPV vaccination specific to their area of jurisdiction;
 - 5. Perform data validation and generate reports regarding accomplishment during the implementation period;
 - 6. Conduct regular consultation and implementation reviews among respective LGU personnel, immunization stakeholders, and other organizational partners to improve service delivery efficiency and address implementation issues/gaps; and
 - Submit timely reports to the DOH and DILG for monitoring and tracking of progress of implementation.

1. 6. The Local Health Centers shall:

- 1. Conduct social and behavior change strategies to support school-based immunization;
 - 2. Deploy trained healthcare workers to conduct immunization sessions;
 - 3. Ensure the availability and proper storage and handling of vaccines and related supplies;
 - 4. Screen the immunization records of students for a missed dose, series of doses, or all vaccines due to the learners:
 - 5. Administer vaccines to eligible students within the school premises;
 - 6. Provide follow-up care and additional vaccinations if required; and
 - 7. Perform the recording, data collection and validation of the number of immunized target populations during the implementation period.

J. H. Professional medical and allied medical associations, academic institutions, non-government organizations, development partners and the private sector shall be enjoined to support the implementation of the catch-up immunization guidelines and disseminate it to the areas of their influence.

For dissemination and strict compliance.

By Authority of the Secretary of Health:

GLENN MATHEW G. BAGGAO, MD, MHA, MSN, FPSMS, FPCHA Undersecretary of Health

Public Health Services Cluster

Annex A: Notification Letter and Consent Form Template



Republika ng Pilipinas Rehiyon____





NOTIFICATION LETTER

			DATE:	
DIVISION:				
SCHOOL:				
ADDRESS:				
Dear Parent Guardian.				
This school as a Public Element and Tetanus—Diphtheria (Td) vaccines to Government Unit (LGU)	ary Secondary School Grade 1 and Grade "	will provide School-Based In Students in coordination with t	nmunization (SBI) of the Department of He	(Measies-Rubelia (Maith (DOH)) and the Lo
This Notification is being issued further questions—clarifications on this man	to you as information of ter, please get in touch v	of the activity that will be con with the Principal School Hear	ducted for SY 2024 -	2025 Should you ha
Thank you very much.				
		Very truly your	5 ,	
		Name of School	ol Head Principal	
	ACKNOWLEDG	EMENT AND CONSENT		
I have read and understood the information i	egarding the intended is	nmunization services to be giv	en to my child.	
Name of the Child			Date of Birth (mm	(44)
Surname	First Name	Middle Name:		
Contact Information	· · · · · · · · · · · · · · · · · · ·		Age	Sex
Centact Number:	School:			
PRE-VACCINATION CHECKLIST (PC l'air consent it required before your chit apolitat chinals check its if any condition a, My child had a history of severe allerg My child has a severe illness: Primary immune – deficiency dis Suppressed immune response from Leukenia Lymphoma Other generalized malignancies None, my child is relatively healthy	d can be immuniced at opises to your childs y to measles-containing rase	school Request clearance f	om your physician (*	am of the following
CONSENT FOR DALICNIZATION	Plans chark	in the bez provided;		
Ves. I will allow my child to be provided in MR. Idit Grade 1 (MR. Idit). Grade 1 (MR. Idit). No. I will not allow my child to recent I understand that by opting out of the signing this warrer. I admostedge that the required school immunications.	led the minimization service the minimization service the minimization service required minimizations. In	res as per DOH recommendation because child may be at a higher risk of o		
	Name and Signature	of Parent Guardian		



Republika ng Pilipinas Rehiyon____





NOTIFICATION LETTER

			DAIL:	
DIVISION:				
SCHOOL:		_		
ADDRESS:		_		
ADDRESS:		-		
Dear Parent Guardian				
This school as a Public El (HPV) Veccine to Grade 4 Female	ementary Secondary Scho students in coordination wi	ol will provide School-Base th the Department of Health	d Immunization (SBI) of I (DOH) and the Local Gove	Human Papillomavir remest Unit (LGU)
This Notification is being further questions clarifications on the	issued to you as information us matter please get in toucl	n of the activity that will be h with the Principal - School	conducted for SY 2024 = Head	2025. Should you have
Thank you very much				
		Very truly	yours,	
		Name of S	ichcol Head Principal	
	ACKNOWLED	GEMENT AND CONSEN	न	
I have read and understood the inform	ation regarding the intender	immunization services to b	e given to my child	
Name of the Child			Date of Birth (mas/	(44/yyyy)
Surname	First Name:	Middle Name		
C-1-174	··			
Contact Information Contact Number	School		Age .	Sex
Consci Namoer	SCHOOL.			
PRE-VACCINATION CHECKLE				
John content to required before yo applies ritually check to fram const. My child had a history of seven. My child has a severe illness. Primary unmine – deficien	inen applies to vour childi r allergy to human papullom		१८८ विकास ३०६८ वृत्रेष्ठ्यात्राक्याः इ	iann of the following
Suppressed immune respon				
Leukemia				
Lymphoma				
Other generalized maligna				
None, my child is relatively hea	atn's			
CONSENT FOR DIDIUNIZATIO	N			
		ck in the bex provided;		
Yes I will allow my child to b Oracle 1 MR Tai	e provided the immunization se	maces as per DOH recommenda	hea	i
☐ Orade 1 31R 131				
No I wall not all meny child :	c teceie me mimmiration set.	ace pecanae		
	edge that I have read and under	my child may be at a higher fit stood the information provided a		
	Name and Signatu	re of Parent Guardian		

Annex B: Recording Form 1 - Masterlist of Grade 1 Students

Percenting Form 1: Mesterfist of Oracle 1 Stadents SCHOOL-BASED IMMUNIZATION

14:	ı	Number of Vacc na Unitated in Vieles:
Z K	Number of Visco Number of Visco	Number of visoo
Name of Schoo:	Detrict Music pelity:	Date:
Report:	Berngey	C ty/Province:

			a i	Age to the state of the state o	Septembra Septem
*	1400 H	z >	MCV 2 V H	MOV1 MOV2 Y M	MOV. MOV.
1 1 1 1 1					

Name & Signature of Recorder	
Name & Stynature of Vacchalor 2	Code Reasons 10 Leck of trust in the veccinator 11 Claid part resourced from three hospitals, the parent's canginers refused:
Name & Signature of Vaccinator 1	DOS FOR BENES LUNIALCOMATED It all that apply for the HH) Massens Parent was absent/ away from home Fear of vectors Side effect Vactors safety issues (dengue vactore experience, past adverse experience, etc.) Child allowedy has complete routine vactore experience, past adverse experience, etc.)
Name & Algorithms of Supervisor	REASONS FOR BEING LINEARCCHARTED [Select all that apply for the HH) Code Reasons 1 Patent was absent/away from home 2 Fear of viscone Side effect 3 Viscone safety fixines (dengue vaccine experience, past adverse a Child dengue vaccine experience, past adverse a

- so parents refused
 5 Fear of COMD transmission
 6 Vaccine perceived to be not effective, of low-quality or on near-expiry
 7 Client is a newborn and parents believed that her/his child is too young to be
- given vaccination

 8. Child was already vaccinated by private MD, against advised by private MDs, thus parents/ caregiver rehisted

 9. Peculiar personal beliefs or misconceptions of the parents or caregiver on vaccination, Against infigure beliefs.
- Unswere of the campaign
 Vaccine beam did not with
 Vaccine beam did not with
 Child was a from a different are
 Child was accenty sick or not feeling well
 Do not know, declined to respond
 Outright natural
 Other (specify) *********

Annex C: Recording Form 2 - Masterlist of Grade 7 Students

SCHOOL-BASED IMMUNIZATION Recording Form 2: Mesteriff of Grade 7: Blugerits

Regon:	Name of Sohoo :		260 ox	l												
	Day of 38 chickens					WR; Number of twee he Received to we set	20 30 B	G. 750			i i	Td: Number of twee to Base and in their	3	9	į	
		1				"Author of vace na Usecom visiti."	3			ı	5	Number of Vitocine Usedijn v a str				
City Province:	Dere:	ŀ				Number of viscone Unused in visiting	2 to 201	v n ibeen			ş	Number of Vaccine Unused in vals:	26 U.S.	SEV UNE		
To be filed out by Loos' Health Center - Veconation Team	Veccuation Team			To se the out	To be titled out by Meccinetion Team	W.										
Neme		Date of Sirts		Date of MCV Received	Comment St.	<u> </u>	Mot today	51		3	Neothe Given		ľ			
(Marmanne, First Harne, 600)		MADOWYY	-	MCV1 MCV2	H A	Year Teach	>	1	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	2 WH 7	3:	2	1			
								H	H	Н	Ц					
~					A (20 4			\dagger	+	+	1				Ī	
8								T	╀	ig	L			T		
ę								Н	H	Н						
•						_		1	+	\dashv						
			T				Ţ	\dagger	+	╬						
6								+		\downarrow	$oldsymbol{\downarrow}$					
C.								Н	Н	Н						
								i				;				
Hame & Signature of Supervace	Kame & Sign	Kame & Signature of Vaccimitor 1			į	Marie & Signature of Vaccinator 2	ccirudor 2				į	Hame & Bignature of Recorder	after of R	corder		
	as FOX BEING LINVACCINATED al that apply for the HH) Readons Readons Parent was absent away from home test of vaccine Side effect Kectine safety insures (derigue vaccine experience, para adverse experience) Child already lins complete routine vaccination, extra vaccine dose not exist refused test of COVID transmission testine percented to be not effective, of fore-quality or on near-expiry Client is a newborn and parents befored that her/fils child is too youn sistemation Al Canegues refused Al Canegues behelve Along Applicat religious behelve	4 G		Code Lack of trust in the vaccinator 11 Child just recovered from inters or just dischaged from the begins, the parent's caregiver reflused. 22 Unawer of the campagn 23 Unawer of the campagn 24 Child was a from a different area 25 Child was acuterly sict or not feeling well 26 Do not know! declined to respond 27 Outright reflusal 28 Other (specufy):	raccinator from siness or giver refused- page gravative X visik ziferent ava ch on not leelin ned to respons	Just dischaged	ion the									

Annex D: Recording Form 3 - Masterlist of Grade 4 Female Students

Recording Form 3: Masterlist of Grade 4 Female Students SCHOOL-BASED IMMUNIZATION

Reg on:	Nerns of Schoo:		300t gn:														
										Š							
Berangay:	District Municipal by:									10 m	of Vision	H RECE	Number of Viscome Received in visits:	 	ı		
										5	of Vacci	2000	Number of Vaccine Used;in v.e.s;				
City Province:	Dina:									₹	of Visocii	\$ C	Number of visceine Unused in visits:				
To be fired out by Local Health Center. Vecomenon Team	Waterwaten Nam				70 Ce (wed	ca pi	To be fired out by reconstion them	Ther									
3	Commission Additions	Date of Strib	3	3	Date of HPV Received		Connect Mg	Ļ		Slok today? Fever, etc		Veccine Given	e is	Ľ			4
(Sumane, Pint Name, Mt		MM/DD/YYYY			HPV 1 MPV 2		2 >	Sergies Sergies	>	2	E A	į	1 Z A4	14			Į
-							<u> </u> _				T			-		T	l
c					_	┝						T	-	\vdash		T	
C											T			H			l
7							_					T	\vdash	\vdash	T		
9						\vdash	L		_		-						
9						\vdash	_										ŀ
4						\vdash								H		T	
6						H	L						_		T		l
G									_			T	-	-	T	T	
υ.													-				
	,																
Name & Signature of Supervacor	Hame & Signature	re of Vaccinator 1			Name & Sq	Tarture o	Name & Squature of Vaccinator 2	1 2	i	N. S.	Name & Signature of Recorder	re of Re	corder				
REASONS FOR BEING UNIVACCHATED (Select all that apply for the 101)																	

8 | | | | | | | | | | |

Parent was absent/ away from home Fear of vaccine Side offect

Reasons

Ç

- Vaccine safety issues (dungue vectine experience, past adverse experience, etc.)
- Child aiready has complete routine vacunation, extra vaccine dose not necessary, so perents refused as
 - Fear of COVID transmission

 - Vaccine perceived to be not effective, of low-quality or on near-expiry. Great is a newborn and parents believed that her/his chied is too young to be
- Child was already vaccinated by private MO, against advised by private MOs, thus given vaccination
 - Peculiar personal beliefs or misconceptions of the parents or caregiver on vaccination, Against religious betefs parents/ caregiver refused

- 10 Lack of trust in the watchator
 11 Child just recovered from illness or just dischaged from the hospital, the parent/caregiver refused:
 12 Unaware of the campaign
 13 Vaccine team did not with
 14 Child was a from a different area
 15 Child was a newly sixt or not keeling well
 16 Do not know declined to respond
 17 Outnight refused
 18 Other (specify): Do not know/ declined to respond Gurnght refusal Other (specify)

Annex E: Summary Reporting Form

School-Based Immunization
DALY SUMMARY AEPORTING Form: PHV Consoldana Accomplishment Form Report

		3	Grade 1				.	9	Grade 4 Female	Private						3	Grade 7			
	jis	1 7	Paul na. al general	i	Tare to d'orbor		1	_	i]	4]*	115	112		I	1	and at all the same
	; ;	. ,	2	, , ,	3	1	215	115	z 1 1	115	2 }	11	!! • · , ··	11	1	. 1	*			2
•			• •			• •				• •		-+ 4	•				• •		• - •	• •
		-							\prod						H	\prod		\prod	11	
:				-									-			+	++			<u> </u>
• .	_				#	.					1									
					\prod			+	H		++	\prod	+			+	-			_
70 to 1	-						•			·			•				•		• -	-
Grade 1: Number of Visoche Received en vlass). Number of Visoche Uneden viels. Number of Visoche Unedelin viels).		6 I í í í	Grade 7: Miniber of Vaccine Received (in vise Number of Vaccine Used(in vise); Number of Vaccine Used(in vise);	Received (in : Used(in visits) Unused(in ve		l i		Grade Humber Number	Grade 4 Female: MFV: Number of Vaccine Number of Vaccine Number of Vaccine	Grade 4 Fernale: MFV: Number of Viscone Received on vasis; Number of Viscone Usedon visis; Number of Viscone Unusedin visis;	Jages La									
Tc. Number of Vaccine Received on view; Number of Vaccine Used(in view); Number of Vaccine Uneed(in view);		ř ž ž Ž	Tet. Number of Vaccine Received (in visit): Number of Vaccine Used(in visit): Number of Vaccine Unsed(in visit):	Pacaved (in: Usadijn vlats) Unusadijn va		1														

Annex F: Flow and Submission of Reports

Levels of Implementation	Type of report	Responsible Person	To be Submitted to	Schedule of Report
	Recording Form 1: Masterlist of Grade 1 Students			
School	Recording Form 2: Masterlist of Grade 4 Students	Local Health Center/Vaccination Team	RHU	Daily
	Recording Form 3: Masterlist of Grade 4 Students			
RHU	Consolidated accomplishment report by Schools per Municipalities	RHU Midwife	РНО/СНО	Weekly
РНО/СНО	Analysis report of municipalities	Provincial/City NIP Coordinator	RHO	Weekly
RHO	Bulletin report of prov/city	Regional NIP Coordinator	CO-NIP	Weekly
СО	Bulletin report of CHDs	DPCB NIP	PHSC U	Weekly

Annex G: Quick Health Assessment Form

QUICK HEALTH ASSESSMENT FOR SCHOOL-BASED IMMUNIZATION (MR, Td, and HPV Vaccination)

Name of the Child			Dute of Birth	(mm/dd/yyyy)
Surrame:	First Name:	Middle Name:		
Contact Information	<u> </u>		Age	Sex
Contact Number:	Name of Barang	zay (School):		T +
School:	_1			1
	QUICK HE	ALTH ASSESSMENT	heck (V)	
Questions	Yes	No	Decision	Remarks
 Does the child have fever (≥37.6²C)? 			If Yes, DEFER vaccination; refer for medical management	Temp:
(23 n. U C).			and set a define date for the vaccination	
Date of last meastruation, if applicable:			If pregnant or suspected to be, DO NOT GIVE MR HPV Vaccine	
Note: • Mainutrition, low-grade not be considered as cons	ontraindications.			linesses should
Assessed by:	•			· · · · · · · · · · · · · · · · · · ·
	ture over printed n	ame of the health work	er/screener	
Date (mm dd יציררי):				

Annex H: School-Based Immunization Card Template

Hading Ver-cirrenties Card for School-age Children					
Child's name:					
Date of birth:					
Vaccine Type	Date	(Vaccination gi	ven) Date		
MR (Measles-Rubella)	st. of bearing				
TD (Tetanus-Diphtheria)					
HPV* (Human Papilloma Virus)			Property of the Control of the Contr		
Others:	Ž.				
generalisen entrekker interviewe in de sekteriour vonkker te	Name of the second	A CONTRACTOR OF THE CONTRACTOR			
. B			Ja)	

Annex I: List of Provinces/Cities Implementing HPV Vaccination

CAR

- 1. Apayao
- 2. Ifugao
- 3 Abra
- 4. **Baguio City**
- 5. Benguet
- 6. Kalinga
- Mt. Province

Region I

- 1. Pangasinan
- 2 Ilocos Norte
- **Ilocos Sur**
- La Union 4.
- 5. **Alaminos City**
- Candon City 6.
- Dagupan City
- Laoag City
- San Carlos City
- 10. San Fernando City
- 11. Urdaneta City
- 12. Vigan City

Region II

- I. Batanes
- 2. Cagayan
- 3. Isabela
- 4. Nueva Vizcaya
- 5. Quirino
- 6. Santiago City
- 7. Ilagan City
- 8. Cauayan City
- 9. Tuguegarao City

Region III

- Pampanga
- Zambales 2.
- **Angeles City** 4. Cabanatuan City
- 5. Gapan City
- 6. Mabalacat City
- 7. Palayan City
- 8. Muñoz City
- 0 Nueva Ecija
- 10. Olongapo City
- 11. San Jose City
- 12. San Fernando City

Region IV-A

- 1. Ouezon
- 2. Batangas 3. Cavite
- 4. Laguna
- 5. Rizal
- Antipolo City
- Lucena City

Region IV-B

- **Puerto Princesa City**
- Marinduque 2.
- 3. Occidental Mindoro
- Oriental Mindoro 4.
- 5. Palawan
- 6. Romblon

Region V

- Masbate ١.
- 2. Camarines Sur
- 3 Legazpi City
- 4. Ligao City
- 5. **Tabaco City**

Region VI

- lloilo 1.
- Iloilo City 2.
- Negros Occidental
- **Bacolod City** 4
- 5. Antique
- Aklan 6.
- Capiz
- Guimaras

Region VII

- Cebu
- Cebu City 2.
- 3. Bohol
- 4. **Dumaguete City**
- 5. Negros Oriental
- Lapu-Lapu City Mandaue City 7
- Siguijor
- 9 Tagbilaran City

Region VIII

- ı. Eastern Samar
- 2. Northern Levte
- Northern Samar 3.
- Ormoc City
- Tacloban City 5.
- Borongan City

Region IX

- l. Zamboanga del Sur
- Pagadian City
- Zamboanga City

Region X

- Camiguin
- 2. Bukidnon
- 3. Cagayan de Oro
- 4 Iligan City
- Lanao del Norte
- Misamis Occidental
- Misamis Oriental

Region XI

- Davao Oriental 1.
- **Davao City**
- Davao del Norte 3
- 4. Davao Occidental
- 5. Davao del Sur
- Davao De Oro

Region XII

- 1. North Cotabato
- Sarangani 2
- General Santos City
- South Cotabato
- Sultan Kudarat

Region XIII

- Agusan del Norte 1.
- Agusan Del Sur
- Surigao Del Sur
- 4. Surigao Del Norte 5. **Butuan City**

BARMM

- Lanao del Sur 1.
- 2. Maguindanao Del Sur
- Maguindanao Del Norte
- Sulu 4.
- Tawi-Tawi 5

NCR

- ١. Caloocan City
- Mandaluyong 2.
- Marikina City 3.
- 4. Pasay City
- Quezon City 5.
- 6. **Taguig City** Valenzuela City
- 8. Las Piñas City
- Makati City 9.
- 10. Malabon City 11. Manila City
- 12. Muntinlupa City
- 13. Navotas City 14. Paranaque City
- 15. Pasig City 16. Pateros
- 17. San Juan City

Annex J: List of Immediately Notifiable AEFIs (AO 2023–0007: Revised Omnibus Guidelines on the Surveillance and Management of Adverse Events Following Immunization)

Adverse event	Case definition	Vaccine	
Acute flaccid paralysis (Vaccine associated paralytic poliomyelitis)	Acute onset of flaccid paralysis within 4 to 30 days of receipt of oral poliovirus vaccine (OPV), or within 4 to 75 days after contact with a vaccine recipient and neurological deficits remaining 60 days after onset, or death.	OPV	
	Notifiable if the onset is within 3 months after immunization		
Exaggerated acute allergic reaction, occurring within 2 hours after immunization, characterized by one or more of the following: Wheezing and shortness of breath due to bronchospasm One or more skin manifestations, e.g. hives facial oedema, or generalized oedema. Less severe allergic reactions do not need to be reported. Laryngospasm/laryngeal oedema Notifiable if the onset is within 24 to 48 hours after			
Anaphylaxis Severe immediate (within 1 hour) allergic reaction leading to circulatory failure with or without bronchospasm and/or laryngospasm/laryngeal oedema. Notifiable if the onset is within 24 to 48 hours after		All	
	immunization		
Arthralgia	Joint pain usually including the small peripheral joints. Persistent if lasting longer than 10 days, transient: if lasting up to 10 days	Rubella, MMR	
	Notifiable if the onset is within 1 month after immunization		
Brachial neuritis	Dysfunction of nerves supplying the arm/shoulder without other involvement of the nervous system. A deep steady, often severe aching pain in the shoulder and upper arm followed in days or weakness by weakness and wasting in arm/shoulder muscles. Sensory loss may be present, but is less prominent. May present on the same or the opposite side to the injection and sometimes affects both arms.	Tetanus	
	Notifiable if the onset is within 3 months after immunization		
Disseminated BCG infections	Widespread infection occurring within 1 to 12 months after BCG vaccination and confirmed by isolation of Mycobacterium bovis BCG strain. Usually in immunocompromised individuals.	BCG	
		Measles- containing, Pertussis- containing	

	one day or more distinct change in behavior lasting one day or more. Needs to occur within 48 hours of DTP vaccine or from 7 to 12 days after measles or MMR vaccine, to be related to immunization.	
Hypotonic, hyporesponsive episode (HHE or shock-collapse)	Event of sudden onset occurring within 48 [usually less than 12] hours of vaccination and lasting from one minute to several hours, in children younger than 10 years of age. All of the following must be present: Limpness (hypotonic) Reduced responsiveness (hyporesponsive) Pallor or cyanosis — or failure to observe/ recall	Mainly DTP, rarely others
Injection site abscess	Fluctuant or draining fluid filled lesion at the site of injection. Bacterial if evidence of infection (e.g. purulent, inflammatory signs, fever, culture), sterile abscess if not. Notifiable if the onset is within 7 days after immunization.	All
Lymphadenitis (includes simple and suppurative lymphadenitis)	Either at least one lymph node enlarged to >1.0 cm in size (one adult finger width) or a draining sinus over a lymph node. Almost exclusively caused by BCG and then occurring within 2 to 6 months after receipt of BCG vaccine, on the same side as inoculation (mostly axillary). May develop as early as two weeks after vaccination, most cases appear within six months, and almost all cases occur within 24 months.	BCG
Osteitis/ Osteomyelitis	Inflammation of the bone with isolation of Mycobacterium bovis BCG strain. Notifiable if the onset is between 1 and 12 months after immunization	BCG
Persistent inconsolable screaming	Inconsolable continuous crying lasting 3 hours or longer accompanied by high-pitched screaming. Notifiable if the onset is within 24 to 48 hours after immunization	DTP, Pertussis
Occurrence of generalized convulsions that are not accompanied by focal neurological signs or symptoms. Febrile seizures: if temperature elevated >38°C (rectal) Afebrile seizures: if temperature normal Notifiable if the onset is within 14 days after immunization		All, especially DTP, MMR Measles
Acute onset of severe generalized illness due to bacterial infection and confirmed (if possible) by positive blood culture. Needs to be reported as a possible indicator of program error. Notifiable if the onset is within 7 days after immunization		All
Severe local reaction	Redness and/or swelling centered at the site of injection and one or more of the following: Swelling beyond the nearest joint	All

	Pain, redness, and swelling of more than 3 days duration Requires hospitalization. Notifiable if the onset is within 7 days after immunization. Local reactions of lesser intensity occur commonly and are trivial and do not need to be reported.	
Thrombocytopenia	Serum platelet count of less than 150,000/ml leading to bruising and/or bleeding Notifiable if the onset is within 3 months after immunization	MMR
Toxic shock syndrome (TSS)	Abrupt onset of fever, vomiting and watery diarrhea within a few hours of immunization. Often leading to death within 24 to 48 hours. Needs to be reported as a possible indicator of program error. Notifiable if the onset is within 24 to 48 hours after immunization	All

^{*}Brighton collaboration has developed case definitions for many vaccines reactions and is available at: www.brighton collaboration.org. Reference: Manual of Procedures for Surveillance and Response to AEFI, 2014